Adaptimmune Therapeutics Company
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
Technology:
AgeTech Companies, CAR-T therapy, Cell based gene therapy
Industry:
Healthcare, Public
Headquarters:
Oxton, York, United Kingdom
Founded Date:
2008-01-01
Employees Number:
251-500
Funding Status:
IPO
Investors Number:
16
Total Funding:
399500000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2021-09-07
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership